The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
Normal shipments will resume for all dosage forms of Eli Lilly’s GIP/GLP-1 receptor agonist Mounjaro (tirzepatide) in Japan, beginning early next month, the company and its distribution partner Mitsubishi Tanabe Pharma said on May 15. Shipment restrictions will be lifted…
To read the full story
Related Article
- Mounjaro Logs 5.6 Billion Yen in Q3 YTD despite Curbed Shipments: Mitsubishi
February 8, 2024
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Novo Nordisk Expects to Lift Restrictions on Ozempic Shipments in Early January
December 14, 2023
- Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
November 17, 2023
- Shipment Restrictions Now Hit All Versions of Mounjaro in Japan
August 8, 2023
- Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
- Ozempic Shipment Suspension Expected from March: Novo
March 1, 2022
BUSINESS
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- Drug Wholesalers Slam “No-Discussion” Decision on FY2027 Off-Year Price Revision
December 25, 2025
- JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
- Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…